511.84 A Twelve Month, Open-Label, Safety Trial of Flibanserin 50 Milligrams

Sponsor

Boehringer Ingelheim Pharmaceuticals, Inc.

Principal Investigator

Dr. John Thorp, Obstetrics and Gynecology

Project Run Dates

10/24/2006 to 8/1/2010

Total Award Amount

$160,474.56

 

Summary

This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria.

Associated Publications and other materials

Study Report Detail on Clinical Trials.gov

Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. via PubMed

 

Associated Award Numbers: A07-0688-002, A07-0688-003, A07-0688-004, A07-0688-005, A07-0688-006, A07-0688-007, A07-0688-008, A08-0275-002, A07-0688-009, A07-0688-010, A07-0688-011, A08-0275-003, A07-0688-012, A08-0275-004, A08-0275-005, A08-0275-006, A08-0275-007, A08-0275-008, A08-0275-009, A08-0275-010, A08-0275-011, A07-0688-013, A08-0275-012, A08-0275-013, A08-0275-014, A08-0275-015, A08-0275-016